Development, In Vitro Characterization, Antitumor and Aerosol Performance Evaluation of Respirable Prepared by Self-nanoemulsification Method

Abstract

Poor water solubility and low oral bioavailability limit the clinical application of Erlotinib as an anticancer. For this purpose, we encapsulated erlotinib in the solid lipid nanoparticles (SLN) and designed a spray-dried dry powder inhalable (DPI) formulation. Erlotinib-loaded SLNs were prepared using self-nanoemulsifying and characterized for physicochemical properties. Pulmonary deposition of spray-dried DPI formulation was performed using Next Generation Impactor. The particle size and zeta potential of Erlotinib-loaded SLNs were 300 to 800 nm and −18 to −32 mV, respectively. High drug entrapment efficiency in the narrow range of 80–85% was achieved. Cytotoxicity results indicated that cell growth inhibition of free drug and drug loaded nanoparticles is dose- and time-dependent. Inhalable dry powders prepared from drug-loaded SLNs were found to have a fine particle fraction in the range of 6.92±0.99 –11.24±2.4%, mean mass aerodynamic diameter in the range of 4.52±0.1 to 6.67±0.5 µm. The findings revealed that the proposed inhalable dry powder formulation loaded with erlotinib SLN has potential in lung cancer therapy through pulmonary route.

Key word

drug delivery - bioavailability - anticancer drugs

• References

• 1 Barghi L, Aghanejad A, Valizadeh H. et al. Modified synthesis of erlotinib hydrochloride. Adv Pharm Bull 2012; 2: 119-122
• 2 Ikeda R, Vermeulen LC, Lau E. et al. Isolation and characterization of erlotinib-resistant human non-small cell lung cancer A549 cells. Oncol Lett 2011; 2: 91-94
• 3 Barghi L, Asgari D, Barar J. et al. Synthesis, characterization and in vitro anti-tumoral evaluation of erlotinib-PCEC nanoparticles. Asian Pac J Cancer Prev 2014; 15: 10281-10287
• 4 Stocke NA, Meenach SA, Arnold SM. et al. Formulation and characterization of inhalable magnetic nanocomposite microparticles (MnMs) for targeted pulmonary delivery via spray drying. Int J Pharm 2015; 479: 320-328
• 5 Xu Y, Karmakar A, Heberlein WE. et al. Multifunctional magnetic nanoparticles for synergistic enhancement of cancer treatment by combinatorial radio frequency thermolysis and drug delivery. Advanced healthcare materials 2012; 1: 493-501
• 6 Jenning V, Gohla SH. Encapsulation of retinoids in solid lipid nanoparticles (SLN). J Microencaps 2001; 18: 149-158
• 7 Ruckmani K, Sivakumar M, Ganeshkumar P. Methotrexate loaded solid lipid nanoparticles (SLN) for effective treatment of carcinoma. Journal of nanoscience and nanotechnology 2006; 6: 2991-2995
• 8 Thirupathi G, Swetha E, Narendar D. Role of Isradipine Loaded Solid Lipid Nanoparticles on the Pharmacodynamic Effect in Rats. Drug Research (Stuttg) 2016;
• 9 Tran TH, Choi JY, Ramasamy T. et al. Hyaluronic acid-coated solid lipid nanoparticles for targeted delivery of vorinostat to CD44 overexpressing cancer cells. Carbohydr Polym 2014; 114: 407-415
• 10 Ezzati Nazhad Dolatabadi J, Hamishehkar H, Eskandani M. et al. Formulation, characterization and cytotoxicity studies of alendronate sodium-loaded solid lipid nanoparticles. Colloids Surf B Biointerfaces 2014; 117: 21-28
• 11 Gill KK, Nazzal S, Kaddoumi A. Paclitaxel loaded PEG 5000–DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation. Eur J Pharm Biopharm 2011; 79: 276-284
• 12 Meenach SA, Anderson KW, Hilt JZ. et al. Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. Eur J Pharm Sci 2013; 49: 699-711
• 13 Pilcer G, Sebti T, Amighi K. Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation. Pharm Res 2006; 23: 931-940
• 14 Jaafar-Maalej C, Andrieu V, Elaissari A. et al. Beclomethasone-loaded lipidic nanocarriers for pulmonary drug delivery: Preparation, characterization and in vitro drug release. Journal of nanoscience and nanotechnology 2011; 11: 1841-1851
• 15 Jaafar-Maalej C, Elaissari A, Fessi H. Lipid-based carriers: manufacturing and applications for pulmonary route. Expert opinion on drug delivery 2012; 9: 1111-1127
• 16 Todo H, Okamoto H, Iida K. et al. Effect of additives on insulin absorption from intratracheally administered dry powders in rats. Int J Pharm 2001; 220: 101-110
• 17 Ashurst II, Malton A, Prime D. et al. Latest advances in the development of dry powder inhalers. Pharm Sci Technol Today 2000; 3: 246-256
• 18 Rahimpour Y, Hamishehkar H. Lactose engineering for better performance in dry powder inhalers. Adv Pharm Bull 2012; 2: 183-187
• 19 Carpenter JF, Chang BS, Garzon-Rodriguez W. et al. Rational design of stable lyophilized protein formulations: theory and practice. Pharm Biotechnol 2002; 13: 109-133
• 20 Carpenter JF, Pikal MJ, Chang BS. et al. Rational design of stable lyophilized protein formulations: some practical advice. Pharm Res 1997; 14: 969-975
• 21 Sumby B, Slater A, Atkins PJ. et al. Review of dry powder inhalers. Adv Drug Deliv Rev 1997; 26: 51-58
• 22 Saint-Lorant G, Leterme P, Gayot A. et al. Influence of carrier on the performance of dry powder inhalers. Int J Pharm 2007; 334: 85-91
• 23 Ezzati Nazhad Dolatabadi J, Hamishehkar H, Valizadeh H. Development of dry powder inhaler formulation loaded with alendronate solid lipid nanoparticles: solid-state characterization and aerosol dispersion performance. Drug Dev Ind Pharm 2014; 1-7
• 24 Xia D, Cui F, Gan Y. et al. Design of Lipid Matrix Particles for Fenofibrate: Effect of Polymorphism of Glycerol Monostearate on Drug Incorporation and Release. J Pharm Sci 2014; 103: 697-705
• 25 Bouchemal K, Briançon S, Perrier E. et al. Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimization. Int J Pharm 2004; 280: 241-251
• 26 Espuelas S, Legrand P, Loiseau P. et al. In vitro reversion of amphotericin B resistance in Leishmania donovani by poloxamer 188. Antimicrob. Agents Chemother 2000; 44: 2190-2192
• 27 Mura P, Faucci M, Bramanti G. et al. Evaluation of transcutol as a clonazepam transdermal permeation enhancer from hydrophilic gel formulations. Eur J Pharm Sci 2000; 9: 365-372
• 28 Wang M, Qin L, Li K. et al. The Improvement of the Anticancer Effect of a Novel Compound Benzoic Acid, 2-Hydroxy-, 2-d-ribofuranosylhydrazide (BHR) Loaded in Solid Lipid Nanoparticles. AAPS PharmSciTech 2012; 13: 1348-1354
• 29 Kovacevic A, Savic S, Vuleta G. et al. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure. Int J Pharm 2011; 406: 163-172
• 30 Carvalho TC, Peters JI, Williams RO. Influence of particle size on regional lung deposition – what evidence is there?. Int J Pharm 2011; 406: 1-10
• 31 Zhao M, You Y, Ren Y. et al. Formulation, characteristics and aerosolization performance of azithromycin DPI prepared by spray-drying. Powder Technol 2008; 187: 214-221
• 32 Kho K, Hadinoto K. Dry powder inhaler delivery of amorphous drug nanoparticles: Effects of the lactose carrier particle shape and size. Powder Technol 2013; 233: 303-311
• 33 Meenach SA, Vogt FG, Anderson KW. et al. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols. International Journal of Nanomedicine 2013; 8: 275-293
• 34 Meenach SA, Anderson KW, Zach Hilt J. et al. Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. Eur J Pharm Sci 2013; 49: 699-711
• 35 Patil-Gadhe A, Kyadarkunte A, Patole M. et al. Montelukast-loaded nanostructured lipid carriers: part II pulmonary drug delivery and in vitro-in vivo aerosol performance. Eur J Pharm Biopharm 2014; 88: 169-177
• 36 Littringer EM, Noisternig MF, Mescher A. et al. The morphology and various densities of spray dried mannitol. Powder Technol 2013; 246: 193-200